EXCLUSIVE SAVINGS FOR YOU! www.OTPLinks.com Eli Lilly just dropped their Q3 2025 earnings, and it’s clear the GLP-1 era has entered a new phase. Lilly now controls 6 out of 10 GLP-1 prescriptions in the U.S., driven by massive demand for Zepbound, Mounjaro, and soon Orforglipron, the first oral GLP-1 pill for obesity that could hit the market as early as 2026. In this episode of On The Pen, we break down the key takeaways from Lilly’s call: • Zepbound’s meteoric growth and how 40% of new prescriptions now flow through Lilly Direct • Orforglipron’s global submissions for obesity and type 2 diabetes with a possible priority FDA review that could mean approval in as little as 1 to 2 months • Retatrutide’s next trials for obesity and osteoarthritis pain • What Dave Ricks really meant when he said a $100 GLP-1 pill would “stifle innovation” • The growing tension between innovation and affordability in obesity medicine This isn’t just a numbers story. It’s about access, cost, and the fight for who gets to afford staying healthy. 👉 Share this video if your insurance still excludes GLP-1 coverage. 👉 Tag someone waiting for the oral GLP-1 pill. 👉 Read the full breakdown and watch the next steps unfold at OnThePen.com. 🔗 Read more and subscribe: linktr.ee/manonthemounjaro

WAYS TO SUPPORT MY WORK ⬇️ HTTPS://WWW.OTPLINKS.COM

https://linktr.ee/manonthemounjaro Breaking news! New legislation has been introduced in the House of Representatives concerning compounded medications and the FDA. This move could address the ongoing medication shortage across the country, giving pharmacies more power. The bill is being considered by the Senate and could change existing laws.

Sabina from GLPwinner.com who was in attendance yesterday, sits down in an exclusive OTP interview to discuss yesterday’s s hearing between Eli Lilly and Mochi health. Visit our links: https://linktr.ee/manonthemounjaro

Visit All Our Links: https://linktr.ee/manonthemounjaro Are GLP-1 meds lowering cancer risk? New JAMA Oncology study on Ozempic, Mounjaro, and cancer: If you have ever been told to just eat less and move more, this one matters. A large real world study of adults with obesity found a lower overall cancer risk among people taking GLP-1 medicines like Ozempic and Mounjaro, with the clearest signals in endometrial, ovarian, and meningioma cancers. A small and uncertain uptick in kidney cancer appeared, so we need longer follow up. This is not proof, it is a strong signal that deserves attention and access.

VISIT OUR LINKS: https://linktr.ee/manonthemounjaro TIMESTAMPS: 0:10 Welcome to On The Pen. We just wrapped up listening to the 2025 Q2 Novo Nordisk earnings call... 1:14 Compounded semaglutide is the scapegoat for Novo’s sales slump — let’s unpack it... 2:34 Wegovy growth is slowing, and Novo blames mass compounding in the U.S. despite FDA deadline... 4:10 CVS makes Wegovy the only GLP-1 on formulary for obesity — what that means for access... 6:05 NovoCare Pharmacy struggles to gain traction — only 10% of Wegovy Rx are cash... 7:52 Oral semaglutide for obesity is coming in 2026 with no supply restrictions expected... 9:20 Amycretin enters Phase 3: up to 24% weight loss, both oral and injectable in AMAZE program... 11:08 CagriSema Phase 3b “REDEFINE 11” is now live — testing higher doses and longer use... 12:36 Novo confirms tirzepatide failed to beat dulaglutide for heart protection — semaglutide remains best in class... 14:18 CEO Mike Doustdar’s vision: focus, faster execution, and reallocating budget to obesity pipeline... 15:59 Semaglutide’s unique cardiovascular data explained — FLOW and SUSTAIN-6 trials revisited... 17:46 Wegovy cash channel expansion plans — including Ozempic coming to NovoCare soon... 19:10 What patients need to know when talking to their doctor — current options and what’s next... DESCRIPITON: Novo Nordisk Q2 2025 Earnings: What It Means for GLP-1s, Compounded Semaglutide, Amycretin & Obesity Treatment In this breakdown of Novo Nordisk’s Q2 2025 earnings call, I cover the biggest takeaways for anyone using or considering GLP-1 medications like Ozempic, Wegovy, Rybelsus, and semaglutide for obesity, type 2 diabetes, and related comorbidities. 📉 Novo just lowered their full-year guidance — but why? 💊 1 million patients in the U.S. are estimated to still be on compounded GLP-1 medications, despite the May 22 FDA ruling. Novo says it’s illegal, and they’re calling out pharmacies and telehealth clinics. 🚨 Legal pressure is ramping up. Lawsuits are likely. 🌎 Wegovy is now the ONLY GLP-1 covered for obesity on CVS’s national formulary. This could change everything. 🧪 And perhaps the most exciting update? Novo’s next-gen obesity drug, amycretin, is heading into Phase 3 trials — showing up to 24.3% weight loss in earlier studies. Yes, it’s both oral and injectable. You'll also learn about: The future of oral semaglutide (expected launch in 2026, no supply restrictions) The battle between branded and compounded semaglutide CagriSema’s continued advancement in obesity care Why semaglutide’s cardiovascular benefits are still unmatched, even versus tirzepatide (Zepbound) What new CEO Mike Doustdar plans to do differently This video is for patients, clinicians, advocates, and anyone needing confidence when talking to their doctor about treating obesity today — and what’s coming next.

Breaking News Today from the Trump administration on the cost of GLP-1

Breaking News Today from the Trump administration on the cost of GLP-1 VISIT OUR LINKS: https://linktr.ee/manonthemounjaro

🚨 In this episode of On The Pen, we break down a brand-new mouse study presented at ENDO 2025 that’s turning heads — Zepbound didn’t just help obese mice lose fat, it shrunk their breast tumors. That’s right. For the second time in a week, a GLP-1 medication is showing potential disease-fighting power beyond weight loss. We cover: • How the study was designed • What the results mean for women with obesity • Why this builds on the heart protection data we just reported This is not just about pounds lost. This is about changing the internal environment that fuels disease. Don’t miss this one. 👉 Subscribe for more GLP-1 news, explained from a patient’s perspective. 💬 Drop your thoughts in the comments — especially if this hits close to home. 📰 Read the full breakdown on Substack: [link] #Zepbound #GLP1 #ObesityMedicine #BreastCancer #ENDO2025 #OnThePen #PatientAdvocacy #Mounjaro #Tirzepatide #CancerResearch #GLP1News

All Referenced Links: https://linktr.ee/manonthemounjaro In this episode of On The Pen: Faces of the Fight, I sit down with Connecticut State Senator Matt Lesser, the lawmaker behind one of the boldest health policy moves in recent memory. We talk about Connecticut’s newly passed bipartisan prescription drug affordability bill and the groundbreaking provision buried inside it — a plan to petition the federal government for permission to manufacture their own GLP-1 medications like Ozempic. Senator Lesser explains how this little-known federal law could allow Connecticut to override pharmaceutical patents in the public interest, why the state is spending over 150 million dollars a year on GLP-1s, and how this approach could bring drug prices down not just in Connecticut, but potentially nationwide. We also dig into timelines, political strategy, and the real-world implications of a state trying to break Big Pharma’s pricing model. If you care about access, affordability, and the future of obesity treatment in America, this is one you don’t want to miss.

https://www.getclaimable.com/otp Code OTP10 Saves 10% Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro #zepbound #insurance #cvscaremark

Full article: https://substack.com/@onthepen/note/c-130749661?r=4n3ng9&utm_medium=ios&utm_source=notes-share-action Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro #alzheimer #ozempic #semaglutide

Full Study: https://www.nature.com/articles/s41591-025-03774-9 Get Our Newsletter and Help us Grow! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro #zepbound #mounjaro #foodnoise

Get obesity News to Your inbox: https://www.obesity.news Visit All Our Links: https://www.linktr.ee/manonthemounjaro #retaturtide #cagrisema #onthepen

#ADA2025 #Type2Diabetes #DietSoda Get All The News! https://www.obesity.news Support OTP (all our links): https://linktr.ee/manonthemounjaro

JOIN THE FIGHT HTTP://WWW.ONTHEPEN.SUBSTACK.COM

See all my links: https://linktr.ee/manonthemounjaro

CVS announces major partnership with Novo Nordisk as Lilly announces Q! 2025 earnings. Dave covers it all in today's breakdown. Join the Substack: https://substack.com/@onthepen WAYS TO SUPPORT MY WORK ⬇️ 💊 OVER THE COUNTER ORAL PEPTIDE SUPPLIMENTS: BPC-157 // Can’t Weight // TB4-FRAG // KPV Sign up here and use code “OTP10” to save 10% https://integrativepeptides.com/OTP WHY I TRUST INTEGRATIVE PEPTIDES: 🇺🇸 Made in the USA 📋 CGMP Compliant (FDA oversight of their products) 🧑‍⚕️Trusted and Sold By Doctors and Clinics all over the USA 📕 GET MY BOOK! Decoding GLP-1: A Guide for Friends and Family of Those On The Pen By Dave Knapp https://amzn.to/4gAXrz4 SOCIALS: 📸 : https://www.instagram.com/onthepen.official/profilecard/?igsh=dTRhY3JkYWo1bTIx 🇨🇳: https://www.tiktok.com/@manonthemounjaro?_t=ZP-8sr5PrUuPQl&_r=1 👾: https://discord.gg/ZHeUh7WV 📺: https://youtube.com/@OnThePenPodcast?feature=shared ❌: https://x.com/manonthepen?s=21 💻: https://www.onthepen.com https://www.youtube.com/playlist?list=PLtOcNl0C8quVo0I2YODK-q7cHh4y1r2yB Thank you for tuning in! If you found this content valuable, make sure to like, share, and subscribe to my youtube channel for more updates on GLP-1, obesity, type 2 diabetes, and the latest news on Mounjaro, Zepbound, Wegovy, and Ozempic. Stay informed and entertained with my unique blend of breaking news, humor, and my personal journey. For in-depth articles and resources, visit my website at onthepen.com. 🎙️ New to streaming or looking to level up? Check out StreamYard and get $10 discount! 😍 https://streamyard.com/pal/d/6163227593146368